Understanding Why GE HealthCare Technologies Stock Is Sliding Today.

This afternoon we watched GE HealthCare Technologies drop -2.9% to a price of $80.97 per share. The Large-Cap Medical Electronics company is now trading -13.59% below its average target price of $93.71. Analysts have set target prices ranging from $86.0 to $105.0 per share for GE HealthCare Technologies, and have given the stock an average rating of buy.

The stock has an average amount of shares sold short at 3.2%, and a short ratio of 3.91. The company's insiders own 6.93% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that an average number of institutional investors are invested in the stock, with 73.3% of GE HealthCare Technologies's shares being owned by this investor type.

Institutions Invested in GE HealthCare Technologies

Date Reported Holder Percentage Shares Value
2023-12-31 General Electric Company 13% 61,581,302 $4,986,545,835
2023-12-31 Capital Research Global Investors 11% 51,344,719 $4,157,638,542
2024-03-31 Vanguard Group Inc 11% 48,519,340 $3,928,853,482
2024-03-31 Blackrock Inc. 7% 31,045,833 $2,513,936,279
2023-12-31 State Street Corporation 4% 18,583,969 $1,504,836,861
2023-12-31 Dodge & Cox Inc 4% 16,979,428 $1,374,909,156
2023-12-31 Price (T.Rowe) Associates Inc 3% 12,093,907 $979,304,100
2023-12-31 Geode Capital Management, LLC 2% 7,733,367 $626,209,381
2023-12-31 T. Rowe Price Investment Management, Inc. 2% 7,258,859 $587,786,096
2023-12-31 Hotchkis & Wiley Capital Management, LLC 1% 5,511,973 $446,332,005

Besides an analyst consensus of some upside potential, other market factors point to there being positive market sentiment on GE HealthCare Technologies.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.